Literature DB >> 10065140

[The role of radiotherapy in the treatment of malignant meningiomas].

A DeVries1, J E Munzenrider, T Hedley-Whyte, E B Hug.   

Abstract

PURPOSE: Most malignant meningiomas will recur following surgical resection only. The role of irradiation and radiation dose levels is poorly defined. This study reviews a single institution experience using both, conventional and high doses > or = 60 Gy/CGE radiation regimen. PATIENTS AND METHODS: Between 1974 and 1995 16 patients with histologically proven malignant meningioma underwent radiation therapy (RT). Age at diagnosis ranged between 6 and 79 years (median: 49 years). Three patients reported previous irradiation to the head at least 14 years prior to diagnosis. Ten patients were treated for primary, and 6 patients for recurrent disease. Six patients underwent gross total and 10 patients subtotal resection (Table 1). RT was delivered using conventional, megavoltage photons or combined 160 MeV proton and photon irradiation. Except 1 patient, who died during RT, the radiation doses ranged between 40 and 70 Gy/CGE (= Cobalt Gray Equivalent) (median: 58 Gy/CGE, Table 2).
RESULTS: With median observation time of 59 months (range: 10 to 155 months), actuarial local control rates at 5 and 8 years were 52% and 17%, respectively. Target doses > or = Gy/CGE resulted in significantly improved tumor control (100%) compared to < 60 Gy/CGE (17%) (p = 0.0006, Table 3 and Figure 1). Improved local control translated also in increased overall survival: 87% (> or = 60 Gy/CGE) versus 15% (< 60 Gy/CGE) at 5 years (p = 0.025, Figure 2). At time of analysis, 6/16 patients (38%) were alive. Two patients developed symptomatic brain damage at doses of 59.3 and 72 Gy/CGE.
CONCLUSION: Conformal, radiation therapy with target doses > or = 60 Gy/CGE, in this study by use of combined proton and photon irradiation, can significantly improve chances of long-term local control and survival for patients diagnosed with these challenging tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065140     DOI: 10.1007/bf02753844

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  21 in total

1.  Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull.

Authors:  M Austin-Seymour; J Munzenrider; M Goitein; L Verhey; M Urie; R Gentry; S Birnbaum; D Ruotolo; P McManus; S Skates
Journal:  J Neurosurg       Date:  1989-01       Impact factor: 5.115

2.  Brainstem tolerance to conformal radiotherapy of skull base tumors.

Authors:  J Debus; E B Hug; N J Liebsch; D O'Farrel; D Finkelstein; J Efird; J E Munzenrider
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-12-01       Impact factor: 7.038

3.  Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.

Authors:  L Palma; P Celli; C Franco; L Cervoni; G Cantore
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

4.  Role of radiation therapy in the management of meningioma.

Authors:  R J Carella; J Ransohoff; J Newall
Journal:  Neurosurgery       Date:  1982-03       Impact factor: 4.654

Review 5.  Meningiomas.

Authors:  P M Black
Journal:  Neurosurgery       Date:  1993-04       Impact factor: 4.654

6.  Fractionated stereotactically guided radiotherapy of head and neck tumors: a report on clinical use of a new system in 195 cases.

Authors:  G Gademann; W Schlegel; J Debus; L Schad; T Bortfeld; K H Höver; W J Lorenz; M Wannenmacher
Journal:  Radiother Oncol       Date:  1993-11       Impact factor: 6.280

7.  The role of radiation therapy in the management of intracranial meningiomas.

Authors:  M J Solan; S Kramer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-04       Impact factor: 7.038

Review 8.  Radiotherapy for atypical or malignant intracranial meningioma.

Authors:  M F Milosevic; P J Frost; N J Laperriere; C S Wong; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

9.  [Brain scintigraphy (SPECT) with thallium-201 in primary brain tumors].

Authors:  G Barzen; C Schubert; W Richter; D Calder; M Bärwald; H Eichstädt; R Felix
Journal:  Strahlenther Onkol       Date:  1992-12       Impact factor: 3.621

10.  Radiation therapy in the treatment of meningioma: the Joint Center for Radiation Therapy experience 1970 to 1982.

Authors:  A R Forbes; I D Goldberg
Journal:  J Clin Oncol       Date:  1984-10       Impact factor: 44.544

View more
  4 in total

1.  High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma. A multicentre study.

Authors:  I Compter; K Zaugg; R M A Houben; J T A Dings; G Bosmans; C Buescher; M M H M E Anten; B G Baumert
Journal:  Strahlenther Onkol       Date:  2012-09-09       Impact factor: 3.621

Review 2.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

Review 3.  Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.

Authors:  Barbara M Hahn; Ulrich M H Schrell; Rolf Sauer; Rudolf Fahlbusch; Oliver Ganslandt; Gerhard G Grabenbauer
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma.

Authors:  David Kaul; Volker Budach; Reinhard Wurm; Arne Gruen; Lukas Graaf; Piet Habbel; Harun Badakhshi
Journal:  Radiat Oncol       Date:  2014-03-20       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.